Company Statements, Study Results, Stock Movements, Awards and Stock Splits - Research Report on WebMD, Cerner, Waters, Medidata and Genomic Health Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, November 18, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting WebMD Health Corp. (NASDAQ: WBMD), Cerner Corporation (NASDAQ: CERN), Waters Corporation (NYSE: WAT), Medidata Solutions, Inc. (NASDAQ: MDSO) and Genomic Health, Inc. (NASDAQ: GHDX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

WebMD Health Corp. Research Report

On November 13, 2013, WebMD Health Corp (WebMD) released a statement regarding its editorial integrity. An excerpt from the statement is as follows: "Consistent with major newspapers, broadcasters and other respected publishers; WebMD has an editorial organization that produces content in accordance with well-established editorial policies and practices. The strict editorial practices we have in place ensure that the content we produce is unbiased and done so independent of any third party involvement or control. WebMD also provides advertising and sponsorship opportunities to public and private sector customers that want to reach our consumer or physician audiences. When content appearing on WebMD's sites is funded through advertising or sponsorship, we disclose that funding. As the leading source of health information, WebMD has an obligation to help our audiences understand the changing healthcare landscape, which requires us to cover all sides of a given issue. A review of the content across our consumer and professional sites demonstrates as much. Our Health Care Reform Center reflects WebMD's steadfast commitment to editorial integrity, education and trust." The Full Research Report on WebMD Health Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/c4b8_WBMD

--

Cerner Corporation Research Report

On November 13, 2013, Cerner Corporation's (Cerner) stocks rose 0.55% to $56.78 at the end of trading. Shares of Cerner slipped 0.46% during the previous three trading sessions while the NASDAQ composite and Dow rose to 1.18% and 0.38% respectively over the same period. The Full Research Report on Cerner Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/83ac_CERN

--

Waters Corporation Research Report

On November 12, 2013, the Waters Corporation (Waters) reported that the Company has honored the University of Maryland School of Pharmacy (UMSOP) for its interdisciplinary research using mass spectrometry to discover new and improved drugs to treat cancer, diabetes and infectious diseases. According to Waters, the UMSOP Department of Pharmaceutical Sciences' core Mass Spectrometry Facility under the direction of David Goodlett, PhD, the Isaac E. Emerson Chair of Pharmaceutical Sciences, is the first such institution which has been selected for Waters Centers of Innovation Program honors. Waters added that the honored institution will continue to receive priority access to new technologies, opportunities to influence the development of next-generation research instruments, shared opportunities for collaboration with Waters and priority applications support and funding assistance. University of Maryland, Baltimore President Jay A. Perman, MD, stated, "Today's ceremony is a testament to the achievements of this School. Our new Mass Spectrometry Facility is the largest, most-well equipped and well-staffed facility of its kind in the Mid-Atlantic region and it will enable us to shorten the time it takes to translate research findings into new diagnostics, therapeutics, and preventive procedures that will help patients." The Full Research Report on Waters Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

 http://www.analystscorner.com/r/full_research_report/2fff_WAT

--

Medidata Solutions Inc Research Report

On November 11, 2013, Medidata Solutions Inc (Medidata) announced that a two-for-one split of the Company's common stock was approved by its Board of Directors during the board meeting held on November 7, 2013. According to the Company, the stock split will be structured in the form of a stock dividend. The Company stated that the record date for the spilt is December 2, 2013 and the distribution of the new shares will be made on December 16, 2013 while trading on a split-adjusted basis is expected to begin on or about December 17, 2013. According to Medidata, the stock split will increase the common shares outstanding to approximately 53.6 million. The Full Research Report on Medidata Solutions Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/05dd_MDSO

--

Genomic Health, Inc. Research Report

On November 13, 2013, Genomic Health, Inc. (Genomic Health) reported that the Journal of Clinical Oncology (JCO) has published positive results from a large, independent validation study of the Oncotype DX® colon cancer test in patients from the National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 clinical trial. The Company informed that results of the study provide further confirmation that the Oncotype DX Recurrence Score® (RS) results predict recurrence risk and provide additional information beyond conventional risk factors, enabling better discrimination of absolute benefit of chemotherapy as a function of risk. Genomic Health added that patients with a high Recurrence Score result can be expected to derive larger absolute chemotherapy treatment benefit than patients with a low Recurrence Score result in both stage II and stage III colon cancer. Steven Shak, M.D., Executive Vice President of Research and Development, Genomic Health commented, "With our third published validation study, we continue to demonstrate that our test provides important quantitative and individualized risk assessment that helps guide chemotherapy treatment planning and enables precision medicine." The Full Research Report on Genomic Health, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/db58_GHDX

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


AnalystsCorner.com

SOURCE Analysts' Corner



Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.